Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:20 2025-06-13 am EDT			5-day change	1st Jan Change
269.70 ^CHF	-1.06%		+0.56%	+5.56%

01:46am	Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures	DJ
01:33am	Roche to Advance Prasinezumab Into Phase 3 Trial for Early-Stage Parkinson's Disease	DJ

US FDA Approves Roche's Companion Diagnostic Test for Non-small Cell Lung Cancer Treatment

Published on 05/14/2025 at 23:50

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Roche Holding AG

Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures	01:46am	DJ
Roche to Advance Prasinezumab Into Phase 3 Trial for Early-Stage Parkinson's Disease	01:33am	DJ
Roche to Proceed with Phase Three Development of Investigational Drug for Parkinson's Disease	01:11am	MT
Roche To Advance Prasinezumab Into Phase III Development For Early-Stage Parkinson's Disease	01:03am	RE
Swiss stocks - Factors to watch on June 16	12:56am	RE
Sarepta reports second case of liver failure death after its gene therapy treatment	Jun. 15	RE
Roche Updates Treatment Profile, Dosing Restrictions for Duchenne Muscular Dystrophy Treatment	Jun. 15	MT
Roche Provides Safety Update On Elevidys(TM) Gene Therapy For Duchenne Muscular Dystrophy In Non-Ambulatory Patients	Jun. 15	RE
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	Jun. 13	RE
US FDA approves Nuvation Bio's rare lung cancer drug	Jun. 11	RE
Roche Canada Says Health Canada Authorizes PiaSky	Jun. 11	RE
EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio	Jun. 11	DJ
EQT leads financing round in SpliceBio	Jun. 11	FW
Pharma Mar's Supplemental New Drug Application for Lung Cancer Drug Combo Gets US FDA Priority Review	Jun. 10	MT
Roche's Middle Eastern Arm Launches Sustainable Healthcare Lab Certification Initiative	Jun. 10	MT
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients	Jun. 06	RE
ROCHE HOLDINGS AG : Jefferies is Neutral	Jun. 05	ZD
ROCHE HOLDINGS AG : Deutsche Bank remains a Sell rating	Jun. 05	ZD
Formycon receives market approval in Brazil for Lucentis biosimilar	Jun. 05	DP
Swiss Market Index Extends Rally; Roche Gains on EU Win	Jun. 04	MT
Roche's Evrysdi Tablet Gets EU Clearance for Spinal Muscular Atrophy Treatment	Jun. 04	MT
Roche: EU approves Evrysdi tablet for SMA	Jun. 04	CF
EU Approves New Tablet Formulation for Roche's Spinal Muscular Atrophy Treatment	Jun. 04	MT
EU Approves Roche's Evrysdi Tablet For Spinal Muscular Atrophy	Jun. 04	MT
Roche's Evrysdi Tablet Approved By European Commission	Jun. 04	RE

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

10:00am - Kepler Cheuvreux Virtual CEO CFO Conference

More about the company